Introduction Transfusion medicine (TM) represents a highly dynamic and high-stakes multidisciplinary speciality that lies at the intersection of clinical care, laboratory sciences, and health systems management. Unlike many other areas of medicine, it operates within a supply chain that is both time-critical and uniquely constrained by the biological nature of its products. Blood and its components—such as red blood cells, platelets, fresh and recovered plasma, and cryoprecipitate— are inherently perishable, with shelf lives ranging from just a few days to a few weeks. This short viability period places considerable pressure on healthcare systems to balance the competing demands of maintaining adequate stock while minimizing wastage due to expiry. Furthermore, blood products are sourced from human donors, making supply inherently dependent on donor availability, motivation and mobilization campaigns, seasonal fluctuations, and sociocultural factors.

On the demand side, unpredictable emergencies, major surgeries, trauma, and chronic transfusion-dependent conditions create considerable variability. Thus, transfusion medicine is tasked with orchestrating an extremely delicate equilibrium of supply and demand under conditions of uncertainty and urgency. Adding to this complexity is the remarkable heterogeneity of patients requiring transfusion. Factors such as age, comorbidities, immunological background, alloimmunization history, and rare blood group phenotypes all play a critical role in determining transfusion needs. Inappropriate matching or inadequate prediction of transfusion requirements can lead not only to resource wastage but also to life-threatening outcomes such as hemolytic reactions, alloimmunization, and transfusion-related acute lung injury (TRALI). Historically, conventional statistical methods and heuristic approaches have been used to predict blood utilization patterns, optimize inventory, and reduce risks.

While these methods provided valuable insights, their capacity to handle the large, multidimensional datasets generated in modern healthcare has been limited. In recent years, artificial intelligence (AI) has emerged as a transformative force capable of augmenting, and in some areas surpassing, traditional tools in TM. Machine learning algorithms, deep learning architectures, and natural language processing techniques are increasingly being employed to address challenges ranging from donor motivation and mobilization and blood inventory forecasting to automated serological testing and bedside transfusion decision support. AI models can integrate vast amounts of structured data (such as blood counts, laboratory results, and donor demographics) with unstructured data (such as clinical notes or imaging reports) to derive predictive insights that were previously unattainable.

By learning from historical patterns, these models enable more accurate forecasting of demand, optimization of stock rotation, and identification of patients at risk for adverse transfusion outcomes. outcomes significant is AI’s potential in enhancing safety. Automated image recognition systems are being deployed to improve serology and cross-matching, reducing human error in laboratoryworkflows.Predictiveanalyticscanflagmismatched transfusions, while reinforcement learning approaches are being investigated for personalized transfusion thresholds, tailoring decisions to individual patient physiology rather than applying broad guidelines. At the systems level, AIdriven dashboards and decision-support platforms assist clinicians and administrators in making real-time decisions about allocation and prioritization of limited blood resources. Recent scoping and narrative reviews consistently emphasize the rapid acceleration of AI applications within transfusion medicine.(1-4) They highlight how innovations are moving beyond theoretical frameworks into real-world practice, with pilot ooimplementations already underway in blood banks, clinical laboratories, and hospital wards ORs and ICU.

These reviews also underscore the importance of responsible adoption, with attention to ethical considerations, data privacy, and validation across diverse populations. As the field progresses, AI is not envisioned as a replacement for human expertise but as an essential tool(fig-1) that enhances precision, efficiency, and safety in transfusion practices. Areas for [AI] Tool in Transfusion Medicine. Figure 1. Donor engagement and motivation, Screening, and Adverse Donation Risk Donor engagement represents the cornerstone of a sustainable blood supply chain. Since blood cannot be artificially manufactured, healthcare systems are reliant on the altruism and repeated participation of voluntary, nonremunerated donors. motivtion and retention are therefore perennial challenges in transfusion medicine, especially in the face of demographic shifts, pandemic-related disruptions, and seasonal shortages.

Artificial intelligence (AI) has emerged as a promising tool to improve motivation and retention efficiency and donor experience by leveraging large-scale data collected in blood establishment computer systems (BECS) and national donor registries. Different process of donor recruitment and retention expalained(table 1) Donor recruitment and retention Table 1. motivation and Retention Screening and Eligibility Equity, Fairness, and Ethical Considerations Motivation and Retention Predictive models are increasingly used to identify individuals who are likely to become repeat donors. Machine learning algorithms can analyze donor demographics, previous donation history, geographic location, and even external factors such as weather and public holidays to forecast donation likelihood (5-6). For instance, predictive engagement models can anticipate when a donor is most likely to return, allowing targeted reminders and personalized messaging that improve retention rates.

Similarly, AI-driven analytics can forecast blood drive yields based on seasonal variations, regional demographics, and campaign-specific attributes. This enables blood centers to strategically schedule mobile drives in locations and time periods with the highest predicted impact, thereby reducing operational costs and improving yield consistency7 . Screening and Eligibility The pre-donation screening process, traditionally reliant on standardizedquestionnairesand interpretation,isincreasingly being augmented with AI. Machine learning models can triage donor eligibility by analyzing vitals, prior medical history, and responses to screening questions. Predictive risk scores can help flag donors at higher risk of ineligibility, thereby streamlining the workflow and reducing waiting times (8). Moreover, AI can detect inconsistencies in donor responses that may otherwise escape human reviewers, enhancing the accuracy of donor deferral decisions.

Natural language processing (NLP) has also been explored for analyzing freetext entries in donor questionnaires, helping identify subtle risk markers related to lifestyle or travel history. Prediction of Adverse Donor Reactions Adverse events during donation—such as vasovagal reactions, hematomas, —pose not only risks to donor safety but also threaten retention, as negative experiences reduce the likelihood of repeat donations. AI models trained on large BECS datasets have shown promise in predicting adverse donor reactions by analyzing pre-donation vitals (e.g., blood pressure, pulse, hemoglobin levels), demographic variables, and prior reaction history (9). These models can be used to implement preventive strategies such as tailored hydration protocols, pre-donation counseling, or selection of an alternative donation type (e.g., apheresis vs.

whole blood). Personalized risk assessment enhances donor safety, improves satisfaction, and promotes long-term loyalty to the donation system. Outcome, Fairness, and Ethical Considerations While predictive performance of AI-driven donor engagement and screening systems is strong, concerns about fairness and outcome remain. Certain donor groups—such as women, younger donors, or those from underrepresented ethnic communities—may face disproportionately higher deferral rates if models are not periodically audited and recalibrated (10). For example, reliance on hemoglobin thresholds without considering sex-based differences can inadvertently discourage female donors. Algorithmic bias, if unaddressed, risks undermining trust in blood collection systems. Therefore, ongoing validation across diverse populations and transparent reporting of model performance are essential. Additionally, ethical considerations such as data minimization time reduction and explicit donor consent must be prioritized.

Since AI models may utilize sensitive attributes—including socioeconomic indicators, lifestyle factors, or genetic markers—governance frameworks should ensure that only relevant variables are used, and that donors are informed about how their data is applied. Clear communication fosters trust and aligns with international principles for responsible AI in healthcare. Laboratory microbiology and Immunohematology and Serology Automation Laboratory microbiology and immunohematology forms the backbone of transfusion medicine, providing essential testing to ensure compatibility between donor blood and recipients. Core procedures such as blood grouping, antibody screening, and crossmatching have traditionally relied on manual or semi-automated methods. These conventional approaches, though effective, are vulnerable to limitations such as interoperator variability, subjective interpretation of agglutination strength,time factor and time delays during high workload situations.

The integration of artificial intelligence (AI)-Table-2 and automation technologies into serology laboratories offers a pathway to overcome these challenges, enhancing accuracy, efficiency, and reproducibility. AI- Conventational methods to automation Table 2. Image-Based Algorithms for Agglutination Grading Deep Learning for Genotype-to-Phenotype Mapping NLP for Antibody History and Special Requirements Integration of Automation and Expert Oversight Future Directions and Ethical Considerations Image-Based Algorithms for Agglutination Grading Agglutination strength assessment is a key determinant in antibody detection and crossmatching. Traditionally, grading has depended on visual interpretation by laboratory technologists, introducing variability between readers, especially in borderline or weak reactions. Image analysis algorithms, trained on large datasets of gel or column agglutination images, are now being deployed to provide standardized and objective grading (11).

These algorithms can reliably differentiate between negative, weakly positive, and strongly positive reactions, thereby reducing subjective error and improving consistency across different laboratories. Advanced image-based models also integrate quality control checks, flagging samples where reactions are ambiguous and requiring expert adjudication. Deep Learning for Genotype-to-Phenotype Mapping The increasing availability of next-generation sequencing (NGS) and molecular typing technologies has enabled comprehensive characterization of blood group genotypes. However, translating genotypic data into clinically actionable antigen phenotypes—especially for highly polymorphic blood group systems such as Rh, Kell, Kidd, and Duffy—remains a complex task. Deep learning (DL) models have shown promise in mapping genotypic patterns to antigenic phenotypes with high accuracy (12). These tools facilitate the identification of extended blood group profiles, enabling provision of antigen-matched transfusions for patients with multiple alloantibodies, such as those with aplastic anemia, sickle cell disease or thalassemia who require chronic transfusion support.

By reducing the risk of alloimmunization, genotypephenotype inference helps improve long-term transfusion safety and better patient transfusion outcomes. NLP for Antibody History and Special Requirements A critical aspect of safe transfusion practice is recognition of a patient’s prior antibody history. Antibodies may disappear serologically over time, yet remain clinically significant during futuretransfusions.Manualreviewofpatientrecordsorconsult notestoidentifysuchhistoryisoftenlabor-intensiveandprone to omissions. Natural language processing (NLP) algorithms can automatically analyze electronic health records, flagging prior antibodies, previous transfusion reactions, or unique transfusion requirements such as irradiated, leukoreduced, or washed products (13) . These tools help ensure that critical information is not overlooked during the transfusion decision-making process, thereby reducing avoidable risks. Integration of Automation and Expert Oversight While AI-powered automation significantly improves laboratory workflows, complete replacement of human expertise is neither feasible nor advisable.

Rare serological patterns, unexpected crossmatch incompatibilities, or novel antibodies may not be adequately recognized by models trained on historical datasets. Furthermore, AI systems are subject to “model drift,” where predictive accuracy declines over time due to changing population genetics, testing platforms, or reagent characteristics(14) . Human expert adjudication remains indispensable in reviewing complex or ambiguous cases, providing contextual interpretation, and guiding corrective action. A hybrid model—where AI performs high-volume, routine tasks while human experts focus on complex problem-solving—represents the most effective and safe approach. Future Directions and Ethical Considerations The future of immunohematology automation lies in integrating AI with robotics, molecular typing, and laboratory information systems (LIS). Automated platforms capable of processing samples end-to-end, from initial typing to antibody identification, will likely become standard in high-throughput centers.

However, implementation must address issues of interpretability, data privacy, and equity. For example, genotype-phenotype prediction tools should be validated across diverse ethnic populations to avoid disparities in transfusion safety(15) . Moreover, transparency in algorithmic decision-making are essential for sustained reliability. Component Quality Assessment The quality of blood components directly influences transfusion efficacy and patient outcomes. Traditionally, blood banks have relied on surrogate markers such as storage time, pH, glucose consumption, and visual inspection to infer the quality of platelets, red cells, and plasma. However, these parameters often lack precision and may fail to predict in vivo performance. Recent advances in AI,(table-3) particularly in image analysis and cytometry, are opening new avenues for noninvasive, real-time quality assessment at the unit level.

AI-Quality control Table 3. Platelet Quality Evaluation Red Cell Quality and Hemolysis Prediction Toward Unit-Level Quality-Based Allocation Platelet Quality Evaluation Platelets are especially vulnerable to storage lesions given their short shelf life (5–7 days). One established manual method to gauge platelet viability is “swirling,” which refers to a characteristic light diffraction pattern seen when platelet concentrates are gently agitated. This subjective test is prone to inter-observer variability. AI-driven computer vision models now provide automated, quantitative analogs of swirling, extracting morphological features such as size distribution, granularity, and light scatter (16). Similarly, imaging flow cytometry, augmented by deep learning classifiers, has been applied to measure platelet shape-change metrics during storage. These metrics correlate strongly with functional recovery in vivo, offering a more reliable surrogate for posttransfusion survival (17) .

By identifying units with declining quality, AI-based tools can improve patient safety while reducing wastage. Red Cell Quality and Hemolysis Prediction Red blood cells (RBCs) undergo biochemical and structural changes during storage, including membrane loss, potassium leakage, and hemolysis. Conventionally, unit expiration dates are determined by fixed storage times rather than real-time quality assessments. AI models trained on hemolysis indices, metabolomic profiles, and donor-specific variables can now estimate the risk of hemolysis and storage suitability on a unit-by-unit basis (18) . These tools may support individualized transfusion decisions, ensuring that higher-quality units are reserved for vulnerable populations such as neonates or patients with sickle cell disease. Toward Unit-Level Quality-Based Allocation The integration of these AI-driven assessments has the potential to revolutionize allocation practices.

Instead of traditional “first-in, first-out” (FIFO) systems, transfusion services could implement “first-expiry, first-out” (FEFO) or even “first-quality, first-out” strategies clearly the need supply chain (19) . Such approaches prioritize both expiration timelines and biological quality markers, balancing efficiency with safety. Over time, widespread adoption may extend the usable lifespan of components, reduce wastage, and optimize patient outcomes. Inventory Forecasting and Supply Chain Optimization Efficient management of blood inventories is one of the most pressing challenges in transfusion medicine. The perishable natureofbloodproducts,coupledwithunpredictabledemand, makes forecasting essential to avoid shortages or wastage. AI-prophency (table-4) has proven particularly powerful in this domain, as it can integrate large, heterogeneous datasets to improve accuracy and adaptability.

AI-Prophency Table 4. Forecasting Approaches Hospital-Level Optimization Regional and National Supply Chains Challenges and Ethical Considerations Forecasting Approaches Traditional statistical models such as ARIMA (AutoRegressive Integrated Moving Average) and Prophet have been widely used for time-series forecasting of blood demand. Modern AI approaches expand upon these by incorporating treebased ensemble methods (e.g., random forests, gradient boosting) and deep learning architectures such as long shortterm memory (LSTM) networks (20). These models integrate exogenous variables including surgical schedules, trauma incidence, epidemiological trends, weather conditions, and even public holidays, all of which significantly influence donation and utilization patterns(21) . Hospital-Level Optimization At the hospital level, forecasting models can be coupled with reinforcement learning (RL) to guide dynamic decisionmaking for ordering, issuing, and redistribution of blood products.

RL agents learn optimal strategies by simulating multiple scenarios of supply, demand, and wastage, refining policies to minimize expiries while ensuring adequate supply (22). Such systems are particularly valuable for platelets, given their extremely short shelf life. Early implementations have shown that embedding AI-driven tools into clinician- and technologist-centered workflows can reduce wastage without increasing outdates or shortages (23) . Regional and National Supply Chains Beyond the hospital, AI can also be leveraged at regional or national levels to optimize inter-center redistribution of blood units. Multi-agent optimization models allow blood banks in different locations to share inventory in real time, reducing shortages in high-demand centers while preventing wastage in low-demand areas (24) .

These approaches require robust digital infrastructure and interoperable data platforms but hold promise for more equitable allocation of scarce resources. Challenges and Ethical Considerations Despite strong evidence for effectiveness, challenges remain. Forecasting models must be continuously recalibrated to account for shifts in healthcare delivery, such as elective surgery patterns or unexpected crises (e.g., pandemics, natural disasters). Transparency and interpretability are also critical, as healthcare providers must trust AI-generated recommendations to act upon them. Finally, ethical considerations such as equitable allocation and avoiding systemic bias in resource distribution are paramount. AI can enhance human aspects knowledge and practice experience(25) . CLINICAL DECISION SUPPORT AND PATIENT BLOOD MANAGEMENT (PBM) Patient Blood Management (PBM) has emerged as a cornerstone of modern transfusion practice, aiming to optimize the care of patients who might need transfusion, improve outcomes, and reduce unnecessary blood use.

Artificial intelligence (AI) provides new capabilities for enhancing PBM(table-5) by predicting transfusion needs, guiding restrictive strategies, and identifying alternatives to allogeneic blood transfusion. AI-PBM Management Table 5. Predicting Transfusion Needs Supporting Restrictive Thresholds and Multi-Parameter Triggers Alternatives to Transfusion Decision Support Characteristics Predicting Transfusion Needs AI models can integrate routine electronic health record (EHR) data—including hemoglobin trends, coagulation parameters, vital signs, and comorbidities through transfusion and post transfusion monitoring to blood donation—to forecast transfusion needs in real time. For example, deep learning (DL) sequence models have accurately predicted platelet transfusions within 24 hoursinhematology–oncologyandintensivecaresettings,allowingbloodbankstoproactivelycrossmatchandaligninventory(26) . Similarly,perioperativemodelscananticipateredcellneedsduringmajorsurgeries,reducingrelianceonemergencytransfusions. Supporting Restrictive Thresholds and Multi-Parameter Triggers Traditional transfusion practice has often been threshold-driven, such as a fixed hemoglobin cutoff (e.g., <7 g/dL).

AI allows for more nuanced, patient-centered triggers by combining multiple variables—hemoglobin trajectory, hemodynamic status, tissue oxygenation, and comorbidity profiles—into a predictive framework (27). This supports adherence to restrictive strategies shown to be safe in many patient groups, while individualizing care for those with higher risk. Alternatives to Transfusion AI-enhanced PBM also incorporates strategies to minimize transfusion needs. Algorithms can recommend alternatives such as intravenous iron, erythropoiesis-stimulating agents (ESAs), or intraoperative cell salvage when patterns suggest transfusion is avoidable (28) . Integration into clinical workflows ensures that clinicians are prompted with options in advance, rather than after transfusion has already occurred. Decision Support Characteristics Crucially, AI in PBM should remain advisory rather than prescriptive.

Decision-support systems must provide interpretable outputs with explanations, display uncertainty estimates, and allow for clinician override (29) . This safeguards clinical autonomy and builds trust in AI systems, while ensuring that patients with unique or unforeseen needs are not disadvantaged. HEMOVIGILANCE AND POST-TRANSFUSION OUTCOMES Hemovigilance start at bedside and end with sourse materialhuman blood donated by a donors. Hemovigilance systems track adverse events from blood donation through transfusion to post-transfusion monitoring. Traditionally, hemovigilance relied on voluntary reporting, manual case review, and registry-based analyses, often leading to under-reporting and delays in recognition of emerging risks. AI(table 6) offers powerful tools for enhancing detection, classification, and feedback loops. Role of AI in hemovigilance and oucomes Table 6.

Mining Incident Reports and EHR Narratives Performance and Limitations Linking Donor, Product, and Recipient Data Mining Incident Reports and EHR Narratives Supervised natural language processing (NLP) and machine learning (ML) classifiers can mine unstructured narratives in incident reports, nursing notes, and discharge summaries to identify suspected transfusion reactions (30) . These systems can classify reactions such as transfusion-associated circulatory overload (TACO), transfusion-related acute lunginjury (TRALI), acute hemolytic transfusion reactions (AHTR), and delayed serologic transfusion reactions (DSTR). Automated signal detectioncanreducediscoverylatencyfrommonthstodays,by supporting enhancment responsiveness to safety threats. Performance and Limitations While sensitivity and specificity for acute reactions are promising, recent evaluations show that delayed or serologic reactions remain difficult for automated systems to detect, partly due to subtle clinical presentation and fragmented documentation (31) .

Therefore, expert review remains essential, both for adjudicating flagged cases and for refining AI classifiers through iterative feedback. Linking Donor, Product, and Recipient Data A major strength of AI-enabled hemovigilance lies in its ability to link donor, product, and recipient data across the transfusion chain. Longitudinal models can identify associations between donor characteristics (e.g., age, sex, genetic variants), product processing/storage factors, and recipient outcomes (32) . Such feedback loops allow upstream modifications—such as altered storage protocols or donor eligibility criteria—based on downstream safety outcomes. This holistic, “vein-to-vein” approach represents a paradigm shift in hemovigilance. IMPLEMENTATION CONSIDERATIONS: DATA, VALIDATION, GOVERNANCE The promise of AI tools (table-7) in transfusion medicine is contingent on robust implementation strategies.

Without rigorous validation and governance, even well-performing models risk unintended harm. AI-tools in implementation strategies Table 7. Data Quality and Representativeness Validation and Monitoring Bias Assessment and Fairness Regulatory and Governance Frameworks Data Quality and Representativeness High-quality, representative datasets are the foundation of safe AI. Training data should encompass diverse patient populations across sex, age, ethnicity, comorbidities, and genetic backgrounds to prevent bias (33).high quality documention can easly achived under tree of AI. Equally important is the inclusion of diverse operational contexts—different hospitals, blood centers, equipment and regent vendors, and time periods—to ensure generalizability. Validation and Monitoring External validation across independent sites is mandatory before deployment. Continuous monitoring is required postimplementation to detect model drift, which can occur due to changes in patient populations, clinical practices, or laboratory technologies.

Calibration checks, version control, and performance monitoring dashboards should be routine. Bias Assessment and Fairness Bias detection is a safety requirement, not a secondary consideration. Subgroup calibration analyses (e.g., by sex, age, genotype distribution) are essential to avoid inequitable recommendations or disproportionate deferrals (34) . Transparent disclosure of subgroup performance ensures accountability and fosters trust. Regulatory and Governance Frameworks Many AI models in transfusion medicine qualify as “software as a medical device” (SaMD), falling under regulatory oversight by agencies such as the FDA (U.S.) or EMA (Europe). Regulatory frameworks emphasize safety, efficacy, and transparency, though specific standards for AI are still evolving(35) . Developers and implementers should maintain transparent documentation, including: • Intended use and clinical context • Dataset lineage and preprocessing steps • Performance stratified by subgroups • Known limitations and failure modes PRACTICAL PATHWAY TO ADOPTION DespitetheexcitementsurroundingAIintransfusionmedicine (TM), widespread clinical adoption remains limited.

Moving from promising research prototypes to real-world systems requires careful prioritization, stakeholder engagement, and robust governance. A practical pathway to adoption (table-8) involves starting small, embedding safety mechanisms, prospectively measuring outcomes, and aligning with existing programs. Use of AI from practical pathway to adoption Table 8. Start with High-Utility, Narrowly Scoped Problems Co-Design with End Users Embed Guardrails and Safety Mechanisms Prospective Measurement of Impact Leverage National Programs and Registries Ethical and Legal Readiness Start with High-Utility, Narrowly Scoped Problems AI adoption is most effective when focused on problems with high utility, limited scope, and measurable impact. Examples include platelet inventory optimization—where even a modest reduction in wastage can generate significant cost and safety benefits—or perioperative red cell transfusion prediction, which can reduce emergency shortages (36) .

These “early wins” demonstrate value, build trust, and provide momentum for broader integration. Co-Design with End Users End-user involvement is essential for success. Clinicians, laboratory technologists, transfusion specialists, and blood bank managers should co-design workflows to ensure usability and acceptance (37) . Co-design ensures that models address real pain points rather than theoretical ones and that outputs are presented in an intuitive, actionable manner. For example, technologists may prefer dashboards with colorcoded alerts, while surgeons may want direct EHR-integrated recommendations. Embed Guardrails and Safety Mechanisms AI should never operate unchecked in safety-critical domains like TM. Implementation must include guardrails such as uncertainty thresholds, conservative default policies, and back-out plans (38) .

For example, if prediction confidence falls below a certain threshold, the system should revert to standard operating procedures. Similarly, fallback protocols should exist for system downtime, ensuring continuity of safe practice. Prospective Measurement of Impact Deployment should be accompanied by prospective instrumentation of workflows to measure clinical and operational outcomes. Key metrics include wastage rates, shortage events, time-to-issue, quality of reaction reporting, and patient outcomes (39) . Transparent publication of methods and results not only supports continuous improvement but also contributes to collective learning in the field. Leverage National Programs and Registries Alignment with existing governance structures is critical. National PBM programs, hemovigilance registries, and regulatory frameworks provide infrastructure for oversight, benchmarking, and cross-institutional learning (40) .

Embedding AI tools within these frameworks increases legitimacy, facilitates harmonization, and accelerates dissemination across centers. Ethical and Legal Readiness Ethical principles such as transparency, accountability, and patient consent must be embedded from the outset. Legal frameworks governing AI as a medical device, data sharing, and liability must be anticipated. Institutions that proactively address these considerations will be better positioned for sustainable adoption . OUTLOOK Looking forward, the trajectory of AI in transfusion medicine is poised to move beyond narrow applications toward integrated, adaptive, and system-level innovations. The emphasis will shift from algorithmic accuracy(Table-9) to patient safety, clinical value, and system resilience. AI- from algorithmic accuracy Table 9. Multimodal Modeling Foundation and Domain-Specific Models Learning Health Systems From Metrics to Outcomes Global Collaboration and Equity Multimodal Modeling The next generation of AI tools will combine multiple data modalities, serology images, molecular genotyping, laboratory parameters including, device telemetry, and longitudinal EHR streams .

For example, integrating imaging of agglutination reactions with genomic data and patient transfusion history could enable precise antibody prediction, transforming pretransfusion testing. Foundation and Domain-Specific Models General-purpose “foundation models,” trained on massive datasets, are increasingly being adapted to healthcare. In TM, small domain-specific language models and multimodal foundation models can be fine-tuned for tasks such as interpreting immunohematology consult notes or predicting transfusion needs across diverse contexts . These models promise adaptability and efficiency but require strong safeguards against hallucinations and biases. Learning Health Systems The ultimate vision is the creation of “learning health systems” for transfusion medicine—where data from every transfusion, transfusion event, and donor contributes to continuous model updating .

Such systems will enable real-time feedback loops, improving predictions and recommendations as practices and populations evolve. Guardrails, drift monitoring, and human oversight will remain critical to ensure safe adaptation. From Metrics to Outcomes Success in AI should no longer be measured primarily by statistical performance metrics such as AUROC or F1-score. Instead, the true yardstick will be patient-centered outcomes: safer transfusions, fewer unnecessary blood compnent, reduced adverse event, and more resilient blood systems . This reframing aligns innovation with the ultimate goal of transfusion medicine—medicine - sustainably improving patient safety and system sustainability. Global Collaboration and Equity Finally, the outlook must address equity. Many AI studies are conducted in high-income settings with robust infrastructure.

Broader adoption requires attention to global diversity, ensuring that models are validated in resourcelimited settings and across underrepresented populations. International collaboration through registries and consortia will be essential to avoid exacerbating disparities. RECOMMENDATIONS 1. Rigorous Validation and Multicenter Trials: Future AI tools in transfusion medicine (TM) should undergo robust multicenter validation across diverse populations and healthcare systems before large-scale deployment. Prospective clinical trials should measure not only algorithmic accuracy but also patient-centered outcomes, workflow efficiency, and cost-effectiveness. 2. Human-in-the-Loop Integration: AI systems should augment—not replace—human expertise. Embedding transfusion specialists and laboratory technologists in AI-assisted workflows ensures contextual interpretation, safety checks, and continuous performance calibration. 3. Ethical, Transparent, and Fair AI Practices: Developers and institutions must prioritize fairness audits, explainability, and equitable performance across age, sex, ethnicity, and geographic subgroups.

Transparent documentation of datasources,biases,andlimitationsshouldbemandatory. 4. Standardized Data Infrastructure: Establishing interoperable, high-quality digital databases across blood centers and hospitals is essential. Integration with existing Blood Establishment Computer Systems (BECS), Laboratory Information Systems (LIS), and Electronic Health Records (EHR) will enhance data sharing , realtime analytics and introduction of digital foot print.. 5. Governance and Regulatory Alignment: National transfusion services should collaborate with regulatory bodies to define clear guidelines for AI as a medical device (SaMD). Continuous post-market monitoring, version control,anddriftdetectionmustbecomestandardpractice. 6. Capacity Building and Training: Incorporating AI literacy and data science principles into transfusion medicine curricula will empower clinicians, technologists, and administrators to interpret and govern AI responsibly. 7. Global Collaboration and Resource Equity: International networks and registries should be leveraged to share datasets, benchmarks, and best practices, ensuring that AI tools developed in high-resource settings are adaptable to low- and middle-income countries without exacerbating disparities.there are many ongoing scientific and technical development of AI supporting and improving the health systems.

Conclusion Artificial intelligence is redefining the landscape of transfusion medicine by supporting enhancement of safety, precision, and operational efficiency across the donor-torecipient continuum. From predictive donor engagement and automated serology to dynamic inventory forecasting, patient blood management, and hemovigilance, AI’s potential impact is transformative. However, realizing this promise requires rigorous validation, transparent governance, and ethical stewardship. AI should be viewed as a collaborative partner—amplifying human expertise while ensuring patient safety, equity, and sustainability remain at the forefront of transfusion practice. The integration of AI-driven solutions within responsible, well-governed frameworks will pave the way for a more resilient and intelligent transfusion ecosystem.

REFERENCES

1. Wong WK, Stanworth SJ, et al. Machine learning in transfusion medicine: a scoping review. Transfusion. 2023;64(1):162.

2. Li N, Pham T, Cheng C, McElfresh DC, Metcalf RA, Russell WA, Birch R, Yurkovich JT, Tobian AA. Blood demand forecasting and supply management: an analytical assessment of key studies utilizing novel computational techniques. Transfusion Med Rev. 2023;37(4):150768.

3. Lopes MG, Recktenwald SM, Simionato G, Eichler H, Wagner C, Quint S, Kaestner L, et al. Big data in transfusion medicine and artificial intelligence analysis for red blood cell quality control. Transfus Med Hemother. 2023;50(3):163–173.

4. Barzilai M, et al. AI applications in transfusion medicine. 2025. PMID: 12176357.

5. Kauten C, Gupta A, Qin X, Richey G, et al. Predicting blood donors using machine learning techniques. Inf Syst Front. 2022;24(5):1547–1562.

6. Li W, Su CY, Meulenbeld A, Jagirdar H, Janssen MP, Swanevelder R, Bruhn R, Kaidarova Z, et al. Machinelearning models to predict iron recovery after blood donation: a model development and external validation study. Lancet Haematol. 2025;12(6):e431–e441.

7. Glynn SA, Kleinman SH, Schreiber GB, Busch MP, Wright DJ, Smith JW, Nass CC, et al. Williams AE. Trends in incidence and prevalence of major transfusiontransmissible viral infections in US blood donors, 1991 to 1996. JAMA. 2000;284(2):229–235.

8. Barzilai M, Cohen O, et al. AI applications in transfusion medicine: opportunities, challenges, and future directions. Acta Haematol. 2025;154(2):200–215. 9. van Dam I, et al. Comparative analysis of random forest algorithms, XGBoost, and support vector machines for predicting vasovagal reactions during blood donations using heart rate variability and needle fear [doctoral dissertation]. Tilburg University; 2024.

10. Hardy NM, Grady C, Pentz R, et al. Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation. Br J Haematol. 2007;139(5):824–831.

11. Valinsky JE, et al. The analysis of red cells by flow cytometry: applications in immunohematology. In: Flow Cytometry. CRC Press; 2024:169–190.

12. Moslemi C, Sækmose S, Larsen R, et al. A deep learning approach to prediction of blood group antigens from genomic data. Transfusion. 2024;64(11):2179–2195.

13. Tayarani M. Applications of artificial intelligence in battling against COVID-19: a literature review. Chaos Solitons Fractals. 2020;140:110122.

14. Fung AW. Establishing sustainable quality improvement in the clinical laboratory: redesign of the total testing process and digital transformation of routine quality assurance activities. Clin Biochem. 2025;137:110915.

15. Reid ME, Lomas-Francis C, Olsson ML. The Blood Group AntigenFactsBook.3rded.London:AcademicPress;2012.

16. Zhang Z, Zhang P, Wang P, Sheriff J, Bluestein D, Deng Y, et al. Rapid analysis of streaming platelet images by semi-unsupervised learning. Comput Med Imaging Graph. 2021;89:101895.

17. Lewis JE, Cooper LA, Jaye DL, Pozdnyakova O, et al. Automated deep learning-based diagnosis and molecular characterization of acute myeloid leukemia using flow cytometry. Mod Pathol. 2024;37(1):100373.

18. Sowemimo-Coker SO, et al. First-quality-first-out strategies in RBC transfusion management. Vox Sang. 2025;120(3):200–209.

19. Li N, Arnold DM, Down DG, et al. From demand forecasting to inventory ordering decisions for red blood cells through integrating machine learning, statistical modeling, and inventory optimization. Transfusion. 2022;62(1):87–99.

20. Ta-Dinh Q, Pham TS, Hà MH, Rousseau LM, et al. A reinforcement learning approach for the online dynamic home health care scheduling problem. Health Care Manag Sci. 2024;27(4):650–664.

21. Kandil S, Marzbani F, Shamayleh, et al. An IoT-driven framework for blood supply chain management: addressing demand–supply uncertainties in the UAE case study. In: Proceedings of the 2024 IEEE International Conference on Technology Management, Operations and Decisions (ICTMOD). IEEE; 2024:1–7.

22. GenM,LiZ,YunY,etal.SustainableLogisticsSystemsUsing AI-Based Meta-Heuristics Approaches. Routledge; 2024.

23. Kanagarajah A, et al. AI-driven innovation in healthcare product development: challenges and ethical implications. Health Technol (Berl). 2025;15(2):85–94.

24. El-Menyar A, Naduvilekandy M, Asim M, Rizoli S, Al- Thani H, et al. Machine learning models predict triage levels, massive transfusion protocol activation, and mortality in trauma utilizing patients’ hemodynamics on admission. Comput Biol Med. 2024;179:108880.

25. Shander A, Hardy JF, Ozawa S, et al. A global definition of patient blood management. Anesth Analg. 2022;135(3):476–488.

26. Goodnough LT, et al. Patient blood management and AI-enhanced decision support. Lancet Haematol. 2025;12(5):e401–e409.

27. Amann J, Vetter D, Blomberg SN, et al. To explain or not to explain?—Artificial intelligence explainability in clinical decision support systems. PLoS Digit Health. 2022;1(2):e0000016.

28. Clifford GD, et al. NLP-based detection of transfusion reactions in clinical narratives. J Am Med Inform Assoc. 2025;32(4):570–582.

29. De Vries RR, Faber JC, eds. Hemovigilance: An Effective Tool for Improving Transfusion Safety. Hoboken, NJ: John Wiley & Sons; 2012.

30. Klein HG, et al. Will blood transfusion ever be safe enough? JAMA. 2000;284(2):238–240.

31. ObermeyerZ,TopolEJ,etal.Artificialintelligence,bias,and patients’ perspectives. Lancet. 2021;397(10289):2038.

32. Wiens J, Creary M, Sjoding MW, et al. AI models in health care are not colour blind and we should not be either. Lancet Digit Health. 2022;4(6):e399–e400.

33. Warraich HJ, Tazbaz T, Califf RM, et al. FDA perspective on the regulation of artificial intelligence in health care and biomedicine. JAMA. 2025;333(3):241–247.

34. Cancelas JA, Gkoumassi E, Smit Sibinga CT, et al. Clinical blood transfusion and artificial intelligence. In: Clinical Use of Blood: A Different Approach. Springer Nature; 2024:55–7

35. Jacobs M, He J, Pradier MF, et al. Designing AI for trust and collaboration in time-constrained medical decisions: a sociotechnical lens. In: Proceedings of the 2021 CHI Conference on Human Factors in Computing Systems. ACM; 2021:1–14.

36. Kalimouttou A, Stevens RD, Pirracchio R, et al. Harnessing AI in critical care: opportunities, challenges, and key steps for success. Thorax. 2025;80(5):451–459.

37. Trentino KM, Lloyd A, Swain SG, Trentino L, Gross I, et al. Data and metrics for patient blood management: a narrative review and practical guide. Anesth Analg. 2022;135(4):110–121.

38. Wood EM, Ang AL, Bisht A, et al. International haemovigilance: what have we learned and what do we need to do next? Transfus Med. 2019;29(4):221–230.

39. Price WN II, et al. Health Care AI: Law, Regulation, and Policy. Oxford University Press; 2024.

40. AcostaJN,FalconeGJ,RajpurkarP,TopolEJ,etal.Multimodal biomedical AI. Nat Med. 2022;28(9):1773–1784.